Anixa Biosciences Presents Positive Data on its Liquid Biopsy for Early Detection of Breast...

Tailwinds' Take: more positive data just before they meet with the FDA. Important notes from the data include potential "Phase 0" detection and the...

What To Put In Your Stockings: December Preview

This weekend we'll be hanging our stockings on the mantel. Come Christmas morning, they'll be lying on the floor, overflowing with presents. At least,...

Anixa Biosciences To Present Cchek™ Breast Cancer Data at AACR Special Conference on Tumor...

Tailwinds' Take: expecting more positive data out of Cchek. Big meeting with FDA in December will tell us how quickly this product can come...

Anixa Biosciences Presents Positive Data from its A.I. Powered Liquid Biopsy

SAN JOSE, Calif., Nov. 12, 2018 /PRNewswire/ -- Anixa Biosciences, Inc. (NASDAQ: ANIX), a biotechnology company focused on using the body's immune system to fight...

October Review, Earnings Preview

October has a reputation for being a bad month to own stocks. For the current generation of investors, this reputation was earned primarily from...

Anixa Biosciences to Present at SITC Annual Meeting

Tailwinds' Take: Anixa continues to demonstrate nothing but very positive results, so expect more from this presentation. We continue to believe the risk /...

As They Start Approaching the FDA, We Discuss Anixa’s Two Innovative Programs

In recent weeks, Anixa has met with the FDA regarding their CAR-T therapy and has now scheduled a discussion around Cchek for early December....

Anixa Biosciences Announces Scheduling of Pre-Sub Meeting with FDA for its Cchek™ Cancer Diagnostic...

Tailwinds' Take: very positive development getting Cchek in front of the FDA for preliminary discussions, especially how quickly the meeting was accepted. With two...

Moffitt Cancer Center and Anixa Biosciences Announce Completion of Pre-IND Meeting with FDA for...

Tailwinds' Take: although this is a minor delay from previous (best case) guidance, it is still fabulous news that Anixa expects to have a...

Anixa Biosciences Releases Data Presented at AACR Artificial Intelligence Conference

Tailwinds' Take: This is outstanding data. The detection of cancer remains in line with prior releases, but the ability to detect benign versus malignant...

Anixa Biosciences Files Pre-Submission and Requests Meeting with FDA Regarding Cchek™ Artificial Intelligence based...

Tailwinds' Take: with two products approaching FDA submissions for clinical trials, ANIX is positioned for significant catalysts and value generation over the next few...

Anixa Biosciences Appoints Leading Researchers in Immuno-Oncology to its Scientific Advisory Board

Tailwinds' Take: this group of SAB members includes scientists who are working on Anixa's CAR-T therapy, which is a major endorsement of the product...

Anixa Biosciences to Present at Artificial Intelligence Conference

Tailwinds' Take: this is an indication that the company could have potentially huge news soon on differentiating between benign and malignant tumors. As Dr....

ITUS Corporation Changing Company Name to Anixa Biosciences and Stock Ticker Symbol to ANIX

SAN JOSE, Calif., Sept. 28, 2018 /PRNewswire/ -- ITUS Corporation (the "Company") (NASDAQ: ITUS), a biotechnology company focused on using the body's immune system to...

From Cchek to CAR-T, ITUS Is On Track

We got the chance to speak with Dr. Amit Kumar, the CEO of ITUS Corp. this last week. Having heard little about the progress...

Moffitt Cancer Center and ITUS Corporation Announce Scheduling of Pre-IND Meeting with the FDA

Tailwinds' Take: these meetings are important steps towards approval of an IND and are not at all perfunctory as they involve significant time and...

Why Tiny ITUS’s CAR-T Therapy Could Be A Big Deal In Cancer Treatment

For the past few years modifying T-Cells to express Chimeric Antigen Receptors, a practice known as “CAR-T”,  has been the hottest space in cancer...

Moffitt Cancer Center and ITUS Corporation Request Meeting with FDA Regarding Ovarian Cancer CAR-T...

Tailwinds Take: with an aggressive timeline, ITUS' CAR-T therapy could be in humans in less than a year from today. If successful, it would...

ITUS Corporation Releases Results for Cchek™ Breast Cancer Study

Tailwinds' Take: More excellent, albeit early, data out of ITUS. Their Cchek platform is showing amazing efficacy in multiple cancers and has the potential...

ITUS Corporation Announces Second Commercial Focus for Cchek™ will be Breast Cancer

Tailwinds' Take: it appears that ITUS is seeing clinical success in multiple cancer types for them to be selecting a second indication at this...